Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PEG-Irinotecan (JK-1201I) in Solid Tumors
NCT04366648Phase 1Completed
- Sponsor
- JenKem Technology
- Start
- May 2018
- Primary completion
- Mar 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of etirinotecan pegol in solid tumor (7 arms), sponsored by JenKem Technology. Primary endpoints: Safety and Tolerability at 21 days and Pharmacokinetics at 21 days. Started May 2018; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04366648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366648.